Application of PAMPA-models to predict BBB permeability including efflux ratio, plasma protein binding and physicochemical parameters

International Journal of Pharmaceutics

Volumn 395, Issue 1-2, 2010, Pages 182-197

  Mensch, Jurgen ^a   L, Libuse Jaroskova ^a   Sanderson, Wendy ^a   Melis, Anouche ^a   Mackie, Claire ^a   Verreck, Geert ^a   Brewster, Marcus E ^a   Augustijns, Patrick ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

Blood brain barrier; Caco 2; Efflux ratio; LogBB; PAMPA; Permeability; Plasma protein binding; Solubility

Indexed keywords

ARTICLE; BLOOD BRAIN BARRIER; DRUG ABSORPTION; DRUG PENETRATION; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; MULTIPLE LINEAR REGRESSION ANALYSIS; PARALLEL ARTIFICIAL PERMEABILITY ASSAY; PHYSICAL CHEMISTRY; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; REGRESSION ANALYSIS; ALGORITHM; BIOLOGICAL MODEL; CACO 2 CELL LINE; CAPILLARY PERMEABILITY; CHEMICAL STRUCTURE; CHEMISTRY; CLASSIFICATION; DRUG FORMULATION; MEDICINAL CHEMISTRY; METABOLISM; SOLUBILITY; STATISTICAL MODEL; STRUCTURE ACTIVITY RELATION;

DRUG; PROTEIN BINDING;

ALGORITHMS; BLOOD-BRAIN BARRIER; CACO-2 CELLS; CAPILLARY PERMEABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; HUMANS; LEAST-SQUARES ANALYSIS; LINEAR MODELS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77954257369     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.05.037     Document Type: Article

References (45)

1. Abbott N.J. Astrocyte-endothelial interactions and blood-brain barrier permeability. J. Anat. 2002, 200:629-638.
2. Abbott N.J. Dynamics of CNS barriers: evolution, differentiation and modulation. Cell Mol. Neurobiol. 2005, 25:5-23.
3. Abbott N.J., Rönnbäck L., Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 2006, 7:41-53.
4. Abraham M.H. The factors that influence permeation across the blood-brain barrier. Eur. J. Med. Chem. 2004, 39:235-240.
5. Abraham M.H., Hersey A., 2006. In: Testa, B., van de Waterbeemd, H. (Eds.), Comprehensive Medicinal Chemistry, 2nd ed., vol. 5. ADMET/Property-based approaches.
6. Abraham M.H., Ibrahim A., Zhao Y.H., Acree W.E. A data base for partition of volatile organic compounds and drugs from blood/plasma/serum to brain, and an LFER analysis of the data. J. Pharm. Sci. 2006, 95:2091-2100.
7. Avdeef A. Absorption and Drug Development; Solubility, Permeability and the Charged State 2003, John Wiley & Sons, Inc., New Jersey, pp. 116-246.
8. Avdeef A. High throughput measurements of permeability profiles. Drug Bioavailibility, Estimation of Solubility, Permeability, Absorption and Bioavailability 2003, 46-71. Wiley-VCH, Weinheim. H. van de Waterbeemd, H. Lennernäs, P. Artursson (Eds.).
9. Avdeef A. The rise of PAMPA. Expert Opin. Drug Metab. Toxicol. 2005, 1:325-342.
10. Avdeef A., Bendels S., Di L., Faller B., Kansy M., Sugano K. PAMPA - critical factors for better predictions of absorption. J. Pharm. Sci. 2007, 96:2893-2909.
11. Begley D., Brightman M.W. Structural and functional aspects of the blood-brain barrier. Prog. Drug Res. 2003, 61:40-78.
12. Bentz J., Tran T.T., Polli J.W., Ayrton A., Ellens H. The steady-state Michaelis-Menten analysis of P-glycoprotein mediated transport through a confluent cell monolayer cannot predict the correct Michaelis constant Km. Pharm. Res. 2005, 22:1667-1677.
13. Brewster M.E., Noppe M., Peeters J., Loftsson T. Effect of the unstirred water layer on permeability enhancement by hydrophilic cyclodextrins. Int. J. Pharm. 2007, 342:250-253.
14. Brightman M.W., Reese T.S. Junctions between intimately apposed cell membranes in the vertebrate brain. J. Cell Biol. 1969, 40:648-677.
15. Brownson E.A., Abbruscato T.J., Gillespie T.J., Hruby V.J., Davis T.P. Effect of peptidases at the blood brain barrier on the permeability of enkephalin. J. Pharmacol. Exp. Ther. 1994, 270:675-680.
16. Cisternino S., Mercier C., Bourasset F., Rouse F., Scherrmann J.M. Expression, upregulation, and tranport activity of the multidrug-resistance protein Abcg2 at the mouse blood brain barrier. Cancer Res. 2004, 64:3296-3301.
17. Clark D.E. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J. Pharm. Sci. 1999, 88:815-821.
18. Di L., Kerns E.H., Fan K., McConnell O.J., Carter G.T. High throughput artificial membrane permeability assay for the blood brain barrier. Eur. J. Med. Chem. 2003, 38:223-232.
19. Ecker G.F., Noe C.R. In-silico prediction models for blood-brain barrier permeation. Blood-Brain Barriers: from Ontogeny to Artificial Interfaces 2006, vol. 1. Wiley-VCH Verlag GmbH & Co.KGaA, Weinheim, Germany, pp. 403-428.
20. Hammarlund-Udenaes M., Fridén M., Syvänen S., Gupta A. On the rate and extent of drug delivery to the brain. Pharm. Res. 2008, 25:1737-1750.
21. Hitchcock S.A., Pennington L.D. Structure-brain exposure relationships. J. Med. Chem. 2006, 49:7559-7583.
22. Instruction Manual for PAMPA Evolution Permeability Analyzer, 2004. Version 2.2.0, pION Inc.
23. Jeffrey P., Summerfield S.G. Challenges for blood-brain barrier (BBB) screening. Xenobiotica 2007, 3:1135-1151.
24. Kansy M., Senner F., Gubernator K. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J. Med. Chem. 1998, 41:1007-1010.
25. Kerns E.H., Di L., Petusky S., Farris M., Ley R., Jupp P. Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery. J. Pharm. Sci. 2004, 93:1440-1453.
26. Konovalov D.A., Coomans D., Deconinck E., Vanderheyden Y. Benchmarking of QSAR models for blood-brain barrier permeation. J. Chem. Inf. Model. 2007, 47:1648-1656.
27. Krämer S.D., Abbott N.J., Begley D.J. Biological models to study blood-brain barrier permeation. Pharmacokinetic Optimization in Drug Research: Biological, Physicochemical and Computational Strategies 2001, 127-153. Wiley-VCH, Weinheim. B. Testa, H. van de Waterbeemd, G. Folkers, R. Guy (Eds.).
28. Lipinski C.A. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov. Today Technol. 2004, 1:337-341.
29. Masungi C., Mensch J., Van Dijck A., Borremans C., Willems B., Mackie C., Noppe M., Brewster M.E. Parallel artificial membrane permeability assay(PAMPA) combine with a 10-day cell culture as a tool for assessing new drug candidates. Pharmazie 2008, 63:194-199.
30. Maurer T.S., DeBartolo D.B., Tess D.A., Scott D.O. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab. Dispos. 2005, 33:175-181.
31. McIntosh A.R., Bookstein F.L., Haxby J.V., Grady C.L. Spatial pattern analysis of functional brain images using partial least squares. NeuroImage 1996, 3:143-157.
32. Mensch J., Melis A., Mackie C., Verreck G., Brewster M.E., Augustijns P. Evaluation of various PAMPA models to identify the most discriminating method for the prediction of BBB permeability. Eur. J. Pharm. Biopharm. 2010, 74:495-502.
33. Mensch J., Noppe M., Adriaensen J., Melis A., Mackie C., Augustijns P., Brewster M.E. Novel generic UPLC/MS/MS method for high throughput analysis applied to permeability assessment in early drug discovery. J. Chrom. B 2006, 847:182-187.
34. Pardridge W.M. Peptide Drug Delivery to the Brain 1991, Raven Press, New York, pp. 52-88.
35. Pardridge W.M. Transport of small molecules through the blood-brain barrier: biology and methodology. Adv. Drug. Deliv. 1995, 15:5-36.
36. Reese T.S., Karnovsky M.J. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J. Cell Biol. 1967, 34:207-217.
37. Rose K., Hall L., Kier L.B. Modeling blood-brain barrier partitioning using electrotopological state. J. Chem. Inf. Comput. Sci. 2002, 42:651-666.
38. Sugano K., Takata N., Machida M., Saitoh K., Terada K. Prediction of passive intestinal absorption using biomimetic artificial membrane permeation assay and the parallel pathway model. Int. J. Pham. 2002, 241:241-251.
39. Summerfield S.G., Stevens A.J., Cutler L., del Carmen Osuna M., Hammond B., Tang S.T., Hersey A., Spalding D.J., Jeffrey P. Improving the in-vitro prediction of in-vivo CNS penetration: integrating permeability, Pgp efflux and free fractions in blood and brain. J. Pharmacol. Exp. Ther. 2006, 316:1282-1290.
40. Sun H. A universal molecular descriptor system for prediction of LogP, LogS, LogBB, and absorption. J. Chem. Inf. Comput. Sci. 2004, 44:748-757.
41. Urbano-Cuadrado M., Luque-Ruiz I., Gómez-Nieto M.A. QSAR models based on isomorphic and nonisomorphic data fusion for predicting the blood brain barrier permeability. J. Comput. Chem. 2007, 28:1252-1260.
42. van de Waterbeemd H., Gifford E. ADMET in-silico modelling: towards prediction paradise?. Nat. Rev. Drug Discov. 2003, 2:192-204.
43. van de Waterbeemd H., Camenisch G., Folkers G., Chretien J.R., Raevsky O.A. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J. Drug Target. 1998, 6:151-165.
44. Wichmann K., Diedenhofen M., Klamt A. Prediction of blood-brain partitioning and human serum albumin binding based on COSMO-RS σ-moments. J. Chem. Inf. Model. 2007, 47:228-233.
45. Wold S., Sjöström M., Eriksson L. PLS-regression: a basic tool of chemometrics. J. Chemometrics 2001, 58:109-130.